Literature DB >> 11819035

Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test.

John P Redrobe1, Girolamo Calo', Domenico Regoli, Rémi Quirion.   

Abstract

The present study investigated the effects of nociceptin, the peptide nociceptin receptor antagonist, [Nphe(1)]-nociceptin (1-13)-NH(2), and the non-peptide antagonist, J-113397, in the mouse forced swimming test, an animal model used for the screening of potential antidepressant drugs. Additional studies were performed with naloxone to exclude effects on traditional opioid receptors. Intracerebroventricular (ICV) administration of nociceptin (0.01-1 nmole) was devoid of any activity in the mouse forced swimming test, as was intraperitoneal (i.p.) administration of naloxone (1-10 mg/kg). ICV treatment with [Nphe(1)]-nociceptin (1-13)-NH(2) (25 nmole and 50 nmole) induced significant antidepressant-like activity ( P<0.01), as did administration of J-113397 (20 mg/kg, i.p; P<0.05). Open field analysis revealed that acute treatment with these molecules did not induce significant changes in locomotor activity at the doses tested. These results suggest that nociceptin, and its receptor, may play a role in depressive disorders and that the nociceptin system could represent a novel target for the development of new antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11819035     DOI: 10.1007/s00210-001-0511-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  27 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

Review 3.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

4.  Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior.

Authors:  Celia Goeldner; David Reiss; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Hippocampus       Date:  2010-08       Impact factor: 3.899

5.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

Review 6.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

7.  Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.

Authors:  E C Gavioli; C W Vaughan; G Marzola; R Guerrini; V A Mitchell; S Zucchini; T C M De Lima; G A Rae; S Salvadori; D Regoli; G Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-05-25       Impact factor: 3.000

8.  Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.

Authors:  Giovanni Vitale; Valentina Ruggieri; Monica Filaferro; Claudio Frigeri; Silvia Alboni; Fabio Tascedda; Nicoletta Brunello; Remo Guerrini; Carlo Cifani; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2009-08-27       Impact factor: 4.530

9.  Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.

Authors:  Victor A D Holanda; Iris U Medeiros; Laila Asth; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2016-04-30       Impact factor: 4.530

10.  Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats.

Authors:  Andre Der-Avakian; Manoranjan S D'Souza; David N Potter; Elena H Chartoff; William A Carlezon; Diego A Pizzagalli; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2017-03-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.